Daiwa Securities Group’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-102
| Closed | -$2K | – | 1436 |
|
|
2022
Q3 | $2K | Hold |
102
| – | – | ﹤0.01% | 1259 |
|
|
2022
Q2 | $1K | Hold |
102
| – | – | ﹤0.01% | 1342 |
|
|
2022
Q1 | $1K | Hold |
102
| – | – | ﹤0.01% | 1369 |
|
|
2021
Q4 | $1K | Hold |
102
| – | – | ﹤0.01% | 1382 |
|
|
2021
Q3 | $1K | Hold |
102
| – | – | ﹤0.01% | 1304 |
|
|
2021
Q2 | $2K | Hold |
102
| – | – | ﹤0.01% | 1165 |
|
|
2021
Q1 | $2K | Hold |
102
| – | – | ﹤0.01% | 1170 |
|
|
2020
Q4 | $1K | Sell |
102
-159
| -61% | -$1.92K | ﹤0.01% | 1242 |
|
|
2020
Q3 | $3K | Hold |
261
| – | – | ﹤0.01% | 1130 |
|
|
2020
Q2 | $4K | Hold |
261
| – | – | ﹤0.01% | 1132 |
|
|
2020
Q1 | $4K | Hold |
261
| – | – | ﹤0.01% | 1128 |
|
|
2019
Q4 | $6K | Sell |
261
-28
| -10% | -$580 | ﹤0.01% | 1100 |
|
|
2019
Q3 | $6K | Hold |
289
| – | – | ﹤0.01% | 1069 |
|
|
2019
Q2 | $9K | Hold |
289
| – | – | ﹤0.01% | 1061 |
|
|
2019
Q1 | $14K | Buy |
289
+86
| +42% | +$3.79K | ﹤0.01% | 1014 |
|
|
2018
Q4 | $7K | Hold |
203
| – | – | ﹤0.01% | 1033 |
|
|
2018
Q3 | $12K | Hold |
203
| – | – | ﹤0.01% | 1025 |
|
|
2018
Q2 | $14K | Hold |
203
| – | – | ﹤0.01% | 1032 |
|
|
2018
Q1 | $11K | Buy |
+203
| New | +$11.4K | ﹤0.01% | 1027 |
|
Daiwa Securities Group's AERI Position: Q4 2022 in Review
Daiwa Securities Group sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 102 shares — an estimated $2K sold.
Daiwa Securities Group first reported a position in AERI in Q1 2018 and held it in 19 quarters. The position peaked at $14K in Q1 2019. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Daiwa Securities Group reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Daiwa Securities Group sold 102 Aerie Pharmaceuticals shares in Q4 2022, an estimated $2K.
- Daiwa Securities Group first reported a position in Aerie Pharmaceuticals in Q1 2018 and held it in 19 quarters.
- Daiwa Securities Group's Aerie Pharmaceuticals position peaked at $14K in Q1 2019.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Daiwa Securities Group's 13F filing for Q4 2022, filed 6 Feb 2023.